Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G.
Montalban-Bravo G, et al. Among authors: schneider h.
Leuk Res. 2024 May 11;142:107518. doi: 10.1016/j.leukres.2024.107518. Online ahead of print.
Leuk Res. 2024.
PMID: 38744144